DNA methylation inhibitors have become the mainstay for treatment of certain
haematological malignancies. In addition to their abilities to reactivate genes, including …

The most exciting recent advance for achieving durable management of advanced human
cancers is immunotherapy, especially the concept of immune checkpoint blockade …

Epigenetics is a kind of heritable change that involves the unaltered DNA sequence and can
have effects on gene expression. The regulatory mechanism mainly includes DNA …

Although the first studies using DNA demethylating agents at low doses in hematologic
neoplasia and hemoglobinopathies were initiated more than 20 years ago, development of …

Innovative therapies for solid tumors are urgently needed. Recently, therapies that harness
the host immune system to fight cancer cells have successfully treated a subset of patients …

Mitotic cell division increases tumour mutation burden and copy number load, predictive
markers of the clinical benefit of immunotherapy. Cell division correlates also with genomic …

We are at the dawn of an era when epigenetic drugs will be an important weapon in our
arsenal in the war against cancer. Hematological malignancies have provided a promising …

The rapid advances in high‐throughput sequencing technologies have made it more evident
that epigenetic modifications orchestrate a plethora of complex biological processes. During …

In recent years, the tumour microenvironment (TME) of solid tumours has attracted more and
more attention from researchers, especially those non-tumour components such as immune …

Targeting DNA methylation for cancer therapy has had a rocky history. The first reports on
DNA methylation changes in cancer described global loss of methylation, which has been …